Excipient-Induced Pulmonary Vascular Disease: An Underrecognized and Deadly Complication of Opioid Addiction.
Christine M CookSteven Q SimpsonLewis SatterwhitePublished in: Lung (2021)
Despite widespread public health concern regarding opioid misuse and overuse, there is a paucity of literature on the acute and chronic pulmonary vascular and cardiac implications of excipient lung disease. This case series describes the clinical presentation of five adult patients who experienced profound pulmonary hypertension and right heart failure in the setting of confirmed or suspected crushed opioid injection at a single academic center between 2012 and 2019. The clinical characteristics and right heart catheterization data presented in these cases demonstrate the acute intravascular effects of the intravenous injection of crushed opioids and potential for hemodynamic collapse. Moreover, these cases suggest that survivors of acute excipient lung disease may develop chronic pulmonary vascular disease. Further studies are needed to explore the epidemiology and outcomes of oral opioid-induced intravascular excipient lung disease to increase awareness of this life-threatening complication among health care professionals and guide treatment and prevention measures.
Keyphrases
- chronic pain
- pulmonary hypertension
- drug induced
- pain management
- liver failure
- heart failure
- public health
- respiratory failure
- pulmonary artery
- healthcare
- high glucose
- pulmonary arterial hypertension
- aortic dissection
- diabetic rats
- systematic review
- coronary artery
- ultrasound guided
- atrial fibrillation
- left ventricular
- pulmonary embolism
- high dose
- machine learning
- low dose
- type diabetes
- metabolic syndrome
- electronic health record
- extracorporeal membrane oxygenation
- risk factors
- hepatitis b virus
- endothelial cells
- intellectual disability
- big data
- insulin resistance
- intensive care unit
- weight loss
- artificial intelligence
- acute respiratory distress syndrome